Photocure to present at the H.C. Wainwright 21st Annual Healthcare Conference in New York

Published: 3 September 2019Investor conferences

Oslo, Norway, 3 September 2019, - Photocure ASA (OSE: PHO) management will be presenting at the 21st Annual Healthcare Conference to investors and industry peers in New York (US) on September 9 at 10:50 EDT. The conference is sponsored by H.C. Wainwright & Co. The presentation will be posted on www.photocure.com when held on September 9, 2019.

Company contact:
Erik Dahl
Chief Financial Officer
Tel: +47 450 55 000
Email: ed@photocure.com

About Photocure ASA
Photocure, The Bladder Cancer Company, delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, which makes cancer cells glow bright pink, has led to better health outcomes for patients worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit us at www.photocure.com, www.hexvix.com or www.cysview.com

News and events

European Association of Urology (EAU) 2024 congress features new data on modern technology use in bladder cancer care

Photocure to Participate in the 23[rd] Annual Needham Virtual Healthcare Conference

EAU 2024: Photocure Partner Asieris to present the Drug and Equipment Performance Results from the Chinese Phase III Clinical Study of Hexvix in Combination with HD 4K Blue Light Cystoscopy equipment

New Publication: Racial Difference in Detection Rate of Bladder Cancer Using Blue Light Cystoscopy

Canadian Health Authorities approve updated and expanded label for Cysview

Photocure Partner Asieris announces positive international Phase III clinical trial results for Cevira and data presentations at the 2024 EUROGIN Congress and SGO Annual Meeting

Photocure Partner Asieris to Unveil Results of the international multicenter Phase III clinical Study for Cevira, a non-surgical treatment for cervical HSIL, at the 2024 SGO

23 February 2024

Photocure Partner Asieris to present First-ever Results of the international multicenter Phase III clinical Study for Cevira, a non-surgical treatment for cervical HSIL, at the 2024 EUROGIN

22 February 2024

Photocure ASA: Results for the fourth quarter of 2023

21 February 2024

Photocure ASA: Invitation to presentation of 4th quarter and preliminary full year 2023 financial results

19 February 2024

New Photocure White Paper addressing Inequality in Bladder Cancer Care and the importance of Real World Evidence

1 February 2024

Photocure Partner Asieris presented clinical trial and real-world data on Hexvix in China at ASCO GU 2024

29 January 2024

Photocure ASA – Share option grant

21 December 2023

Photocure Partner Asieris to present unpublished clinical trial and real-world data on Hexvix in China at ASCO GU 2024

15 December 2023

SUO 2023 Meeting: New Real World Evidence shows Significant Decrease in Risk of Bladder Cancer Recurrence with Blue Light Cystoscopy

1 December 2023

Photocure Partner Asieris announces New Drug Application acceptance for regulatory review of Hexvix in China

29 November 2023

Subscribe to our newsfeed and be kept up to date with the latest Photocure company news

GLOBAL HEADQUARTERS

Photocure ASA
Hoffsveien 4
0275 Oslo
Norway

E-mail: info@photocure.no

NORTH AMERICA

Photocure INC
202 Carnegie Center
Suite 101, Princeton,
NJ 08540, USA

E-mail: info@photocure.com

EUROPE

Photocure GmbH
Breite Str. 27
40213 Düsseldorf
Germany

E-mail: kontakt@photocure.com

Follow us

Privacy Policy Terms of use

© Photocure 2024